Sonya B Norman1,2,3,4, Ryan Trim1,4, Moira Haller1,4, Brittany C Davis1,5, Ursula S Myers6, Peter J Colvonen1,3,4, Erika Blanes1, Robert Lyons1,7, Emma Y Siegel8, Abigail C Angkaw1,2,4,7, Gregory J Norman4, Tina Mayes1,4. 1. VA San Diego Healthcare System, San Diego, California. 2. National Center for PTSD, White River Junction, Vermont. 3. VA Center of Excellence for Stress and Mental Health, San Diego, California. 4. Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla. 5. James A. Haley Veterans' Hospital, Tampa, Florida. 6. Ralph H. Johnson VA Medical Center, Charleston, South Carolina. 7. San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego. 8. Department of Psychology, University of Texas, Austin.
Abstract
Importance: Co-occurrence of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) is common and associated with psychiatric and functional problems. Understanding whether exposure therapy is tolerable and efficacious for treating PTSD and AUD is critical to ensure that best practice treatments are available. Objective: To compare the efficacy of integrated (ie, targeting both PTSD and alcohol use) prolonged exposure (I-PE) therapy with present-centered integrated coping skills (I-CS) therapy, a more commonly available treatment, in reducing PTSD symptoms and alcohol use. Design, Setting, and Participants: This prospective randomized clinical trial with masked assessments considered 186 veterans seeking Veterans Affairs mental health services. A total of 119 veterans with PTSD and AUD were randomized. Data were collected from February 1, 2013, to May 31, 2017, before treatment, after treatment, and at 3- and 6-month follow-ups. Intention-to-treat analyses were performed. Interventions: Veterans underwent I-PE (Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure) or I-CS (Seeking Safety) therapy. Main Outcomes and Measures: A priori planned outcomes were PTSD symptoms (Clinician Administered PTSD Scale for DSM-5) and percentage of heavy drinking days (Timeline Follow-Back) before treatment, after treatment, and at 3- and 6-month follow-ups. Results: A total of 119 veterans (mean [SD] age, 41.6 [12.6] years; 107 [89.9%] male) were randomized. Linear mixture models found that PTSD symptoms decreased in both conditions, with a significantly greater decrease for I-PE treatment compared with I-CS treatment (treatment × time interaction, -2.83; F3,233.1 = 4.92; Cohen d = 0.41; P = .002). The percentage of heavy drinking days improved in both conditions but was not statistically different between I-PE and I-CS treatment (treatment × time interaction, 1.8%; F3,209.9 = 0.18; Cohen d = 0.04; P = .91). Conclusions and Relevance: The I-PE arm had a greater reduction in PTSD symptoms than the I-CS arm and comparable drinking decreases. The study provides evidence that exposure therapy is more efficacious in treating PTSD than a more commonly available integrated treatment without exposure for comorbid PTSD and AUD. Trial Registration: ClinicalTrials.gov identifier: NCT01601067.
RCT Entities:
Importance: Co-occurrence of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) is common and associated with psychiatric and functional problems. Understanding whether exposure therapy is tolerable and efficacious for treating PTSD and AUD is critical to ensure that best practice treatments are available. Objective: To compare the efficacy of integrated (ie, targeting both PTSD and alcohol use) prolonged exposure (I-PE) therapy with present-centered integrated coping skills (I-CS) therapy, a more commonly available treatment, in reducing PTSD symptoms and alcohol use. Design, Setting, and Participants: This prospective randomized clinical trial with masked assessments considered 186 veterans seeking Veterans Affairs mental health services. A total of 119 veterans with PTSD and AUD were randomized. Data were collected from February 1, 2013, to May 31, 2017, before treatment, after treatment, and at 3- and 6-month follow-ups. Intention-to-treat analyses were performed. Interventions: Veterans underwent I-PE (Concurrent Treatment of PTSD and Substance Use Disorder Using Prolonged Exposure) or I-CS (Seeking Safety) therapy. Main Outcomes and Measures: A priori planned outcomes were PTSD symptoms (Clinician Administered PTSD Scale for DSM-5) and percentage of heavy drinking days (Timeline Follow-Back) before treatment, after treatment, and at 3- and 6-month follow-ups. Results: A total of 119 veterans (mean [SD] age, 41.6 [12.6] years; 107 [89.9%] male) were randomized. Linear mixture models found that PTSD symptoms decreased in both conditions, with a significantly greater decrease for I-PE treatment compared with I-CS treatment (treatment × time interaction, -2.83; F3,233.1 = 4.92; Cohen d = 0.41; P = .002). The percentage of heavy drinking days improved in both conditions but was not statistically different between I-PE and I-CS treatment (treatment × time interaction, 1.8%; F3,209.9 = 0.18; Cohen d = 0.04; P = .91). Conclusions and Relevance: The I-PE arm had a greater reduction in PTSD symptoms than the I-CS arm and comparable drinking decreases. The study provides evidence that exposure therapy is more efficacious in treating PTSD than a more commonly available integrated treatment without exposure for comorbid PTSD and AUD. Trial Registration: ClinicalTrials.gov identifier: NCT01601067.
Authors: Anna Persson; Sudie E Back; Therese K Killeen; Kathleen T Brady; Melanie L Schwandt; Markus Heilig; Åsa Magnusson Journal: J Addict Med Date: 2017 Mar/Apr Impact factor: 3.702
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Lesia M Ruglass; Teresa Lopez-Castro; Santiago Papini; Therese Killeen; Sudie E Back; Denise A Hien Journal: Psychother Psychosom Date: 2017-05-11 Impact factor: 17.659
Authors: C Laurel Franklin; Amanda M Raines; Jessica L Chambliss; Jessica L Walton; Kelly P Maieritsch Journal: J Affect Disord Date: 2018-03-07 Impact factor: 4.839
Authors: Denise A Hien; Huiping Jiang; Aimee N C Campbell; Mei-Chen Hu; Gloria M Miele; Lisa R Cohen; Gregory S Brigham; Carrie Capstick; Agatha Kulaga; James Robinson; Lourdes Suarez-Morales; Edward V Nunes Journal: Am J Psychiatry Date: 2009-11-16 Impact factor: 18.112
Authors: Bradley V Watts; Paula P Schnurr; Lorna Mayo; Yinong Young-Xu; William B Weeks; Matthew J Friedman Journal: J Clin Psychiatry Date: 2013-06 Impact factor: 4.384
Authors: Yvette Z Szabo; Tessa Breeding; Christina Hejl; Rakeshwar S Guleria; Steven M Nelson; Laura Zambrano-Vazquez Journal: J Dual Diagn Date: 2020-06-04
Authors: Jessica C Tripp; Matthew J Worley; Elizabeth Straus; Abigail C Angkaw; Ryan S Trim; Sonya B Norman Journal: Psychol Addict Behav Date: 2020-02-27
Authors: Jessica C Tripp; Moira Haller; Ryan S Trim; Elizabeth Straus; Craig J Bryan; Brittany C Davis; Robert Lyons; Jessica L Hamblen; Sonya B Norman Journal: Psychol Trauma Date: 2020-07-16
Authors: Carla Kmett Danielson; Zachary Adams; Michael R McCart; Jason E Chapman; Ashli J Sheidow; Jesse Walker; Anna Smalling; Michael A de Arellano Journal: JAMA Psychiatry Date: 2020-06-01 Impact factor: 21.596
Authors: Joshua C Gray; Mary Jo Larson; Natalie Moresco; Grant A Ritter; Steven Dufour; Charles S Milliken; Rachel Sayko Adams Journal: Drug Alcohol Depend Date: 2021-02-22 Impact factor: 4.492
Authors: C R Pearson; D Kaysen; D Huh; M Bedard-Gillgan; D Walker; R Marin; K Saluskin Journal: Contemp Clin Trials Date: 2020-06-17 Impact factor: 2.226